Lv1
20 积分 2021-06-04 加入
Antitumour immunity regulated by aberrant ERBB family signalling
19天前
已完结
Ivonescimab: First Approval
28天前
已完结
Cadonilimab: First Approval
28天前
已完结
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial
28天前
已完结
Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice
30天前
已完结
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
1个月前
已完结
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
1个月前
已完结
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
1个月前
已完结
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
1个月前
已完结
Global health 2050: the path to halving premature death by mid-century
1个月前
已关闭
皖公网安备34019202002308
